Patient-Centered Care, Venous Thromboembolism
Conditions
Brief summary
The primary study goal is to improve the quality of care transitions for patients with new episodes of venous thromboembolism (VTE). Primary Outcomes: To measure differences in the quality of care transition, as measured by the Care Transition Measure (CTM)-15 in the investigators target population of patients with incident VTE randomized to either a multicomponent, anticoagulation medical home intervention or usual care. Secondary Major Outcomes: To measure the difference in recurrent VTE, major hemorrhage, all-cause re-admissions, and mortality between the investigators intervention and comparison groups at 30 and 90 days in the investigators target population. Secondary Other Outcomes: To measure patient knowledge, health-related quality of life, and time in the therapeutic range (TTR) for patients on warfarin in the investigators target population.
Interventions
Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
Sponsors
Study design
Eligibility
Inclusion criteria
* hospital admission; * diagnosis of: * VTE (first or subsequent episode); or * DVT of leg or pelvis or upper extremities or other site confirmed by ultrasound or CT scan; or * PE with a positive CT spiral exam, pulmonary arteriogram, CT angiogram, or high probability ventilation perfusion scan. * for whom it is anticipated the treating medical team will prescribe an oral anticoagulant upon hospital discharge.
Exclusion criteria
* Not engaged in Primary Care (has not seen a Primary Care Practitioner within the previous 18 months).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Care Transition Measure (CTM-15) | 30 days post hospital discharge | 15 item measure; measures 4 aspects of quality of transitional care |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Outcome: VTE Recurrence | 30 and 90 days post hospital discharge | Measure the difference in recurrent VTE between intervention and comparison groups. |
| Clinical Outcome: Major Hemorrhage (noted in Medical Record and/or via patient self-report) | 30 and 90 days post hospital discharge | Measure the difference in major hemorrhage between intervention and comparison groups- ISTH 2005 medical definition 14 - 2 unit drop in hemoglobin, 2 unit transfusion, or critical site bleed. \- ISTH 2009 surgical definition 15 - surgical site 2 unit drop or 2 unit transfusion with increase in LOS, hemodynamic compromise, delay in rehab. |
| Other Measure: Patient Knowledge (via questionnaire developed by Mazor et. al. 2007 Patient Educ Counsel and via investigator developed items) | 30 and 90 days post hospital discharge | Measure patient knowledge and attitudes Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns. 2007 Dec;69(1-3):145-57. Epub 2007 Oct 17. |
| Clinical Outcome: Mortality | 30 and 90 days post hospital discharge | Measure the difference in mortality between intervention and comparison groups. |
| Other Measure: Quality of Life (VEINES-QOL/Sym questionnaire or PEmb-QoL questionnaire) | 30 and 90 days post hospital discharge | Measure health-related quality of life for patients on warfarin and time in the therapeutic range (TTR) in our target population |
| Clinical Outcome: Hospital Readmission (any unplanned hospital admissions noted in Medical Record and/or via patient self-report) | 30 and 90 days post hospital discharge | Measure the difference between all cause hospital readmission (post-diagnosis of VTE) between intervention and comparison groups. |
Countries
United States